Taking a look at what insiders are doing to gauge the Aclaris Therapeutics Inc. (ACRS)’s direction


Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Aclaris Therapeutics Inc. shares valued at $382,070 were sold by Walker Neal on Mar 03. At $12.63 per share, Walker Neal sold 30,240 shares. The insider’s holdings dropped to 1,273,202 shares worth approximately $10.03 million following the completion of this transaction.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


Also, Monahan Joseph sold 16,037 shares, netting a total of over 202,615 in proceeds. Following the sale of shares at $12.63 each, the insider now holds 147,724 shares.

Before that, Balthaser Kevin had sold 894 shares from its account. In a trade valued at $11,290, the Chief Financial Officer traded Aclaris Therapeutics Inc. shares for $12.63 each. Upon closing the transaction, the insider’s holdings decreased to 894 shares, worth approximately $41417.28.

As published in their initiating research note from Stifel on December 14, 2022, Aclaris Therapeutics Inc. [ACRS] has been a Buy and the price target has been revised to $29. This represents a 72.83% premium over Wednesday’s closing price. Analysts at Goldman started covering the stock with ‘”a Buy”‘ outlook in a report released in early December. As of October 06, 2022, BTIG Research has initiated its “Buy” rating for ACRS.

Analyzing ACRS Stock Performance

On Wednesday, Aclaris Therapeutics Inc. [NASDAQ: ACRS] rose 6.34% to $7.88. The stock’s lowest price that day was $7.43, but it reached a high of $7.89 in the same session. During the last five days, there has been a drop of approximately -35.62%. Over the course of the year, Aclaris Therapeutics Inc. shares have dropped approximately -49.97%. Shares of the company reached a 52-week high of $18.54 on 01/30/23 and a 52-week low of $5.77 on 03/06/23. A 50-day SMA is recorded $14.55, while a 200-day SMA reached $15.34. Nevertheless, trading volume fell to 1.59 million shares from 15.71 million shares the previous day.

Support And Resistance Levels for Aclaris Therapeutics Inc. (ACRS)

According to the 24-hour chart, there is a support level at 7.58, which, if violated, would cause prices to drop to 7.27. In the upper region, resistance lies at 8.04. The next price resistance is at 8.19. RSI (Relative Strength Index) is 23.72 on the 14-day chart, showing oversold technical sentiment. Moving Average Convergence Divergence (MACD) is at -4.06, which suggests the price will decrease in the coming days. Percent R is at 72.20%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.

Is Aclaris Therapeutics Inc. subject to short interest?

Stocks of Aclaris Therapeutics Inc. saw a sharp steep in short interest on Jan 30, 2023 dropping by -0.34 million shares to 2.65 million. Data from Yahoo Finance shows that the short interest on Dec 29, 2022 was 2.99 million shares. A decline of -12.83% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 6.81 of the overall float, the days-to-cover ratio (short ratio) decline to 6.81.

Which companies own the most shares of Aclaris Therapeutics Inc. (ACRS)?

According to Wellington Management Co. LLP filings, the company currently owns 5,484,013 shares, which is about 8.22% of the total ACRS shares outstanding. The investor’s shares have appreciated by 2,030,160 from its previous 13-F filing of 3453853.0 shares. BlackRock Fund Advisors acquire a 11.97% interest valued at $71.56 million while Rock Springs Capital Management L 0 stake. In its current portfolio, Braidwell LP holds 2,393,985 shares valued at $40.46 million.

In terms of Aclaris Therapeutics Inc. share price expectations, FactSet research, analysts set an average price target of $29.11 in the next 12 months, up nearly 291.36% from the previous closing price of $7.41. Analysts anticipate Aclaris Therapeutics Inc. stock to reach $43.00 by 2023, with the lowest price target being $11.00. In spite of this, 9 analysts ranked Aclaris Therapeutics Inc. stock as a Buy at the end of 2023. On June 15, 2021, Piper Sandler assigned a price target of “an Overweight” to the stock and initiated coverage with a $30.


Please enter your comment!
Please enter your name here